DE69913316D1 - Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate - Google Patents

Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate

Info

Publication number
DE69913316D1
DE69913316D1 DE69913316T DE69913316T DE69913316D1 DE 69913316 D1 DE69913316 D1 DE 69913316D1 DE 69913316 T DE69913316 T DE 69913316T DE 69913316 T DE69913316 T DE 69913316T DE 69913316 D1 DE69913316 D1 DE 69913316D1
Authority
DE
Germany
Prior art keywords
degradable
conjugates
gels
produced
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69913316T
Other languages
English (en)
Other versions
DE69913316T2 (de
Inventor
Milton Harris
Xuan Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debio Recherche Pharmaceutique SA
Original Assignee
Debio Recherche Pharmaceutique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debio Recherche Pharmaceutique SA filed Critical Debio Recherche Pharmaceutique SA
Publication of DE69913316D1 publication Critical patent/DE69913316D1/de
Application granted granted Critical
Publication of DE69913316T2 publication Critical patent/DE69913316T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent
DE1999613316 1998-01-07 1999-01-06 Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate Expired - Lifetime DE69913316T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7068098P 1998-01-07 1998-01-07
US70680P 1998-01-07
PCT/US1999/000594 WO1999034833A1 (en) 1998-01-07 1999-01-06 Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom

Publications (2)

Publication Number Publication Date
DE69913316D1 true DE69913316D1 (de) 2004-01-15
DE69913316T2 DE69913316T2 (de) 2004-11-18

Family

ID=22096751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999613316 Expired - Lifetime DE69913316T2 (de) 1998-01-07 1999-01-06 Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate

Country Status (11)

Country Link
US (7) US6362276B1 (de)
EP (1) EP1053019B1 (de)
JP (1) JP3786832B2 (de)
AT (1) ATE255422T1 (de)
AU (1) AU755051B2 (de)
CA (1) CA2316834C (de)
DE (1) DE69913316T2 (de)
DK (1) DK1053019T3 (de)
ES (1) ES2211033T3 (de)
PT (1) PT1053019E (de)
WO (1) WO1999034833A1 (de)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
WO1998012274A1 (en) 1996-09-23 1998-03-26 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US8003705B2 (en) 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
AU755051B2 (en) * 1998-01-07 2002-12-05 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US7335220B2 (en) 2004-11-05 2008-02-26 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
GB2341185A (en) * 1998-09-07 2000-03-08 Polybiomed Ltd Polymerizable material and adhesive sheet material therefrom; dressings, electrodes and transdermal patches
WO2000015117A1 (en) 1998-09-17 2000-03-23 Focal, Inc. Self-cleaning fluid delivery device for medical applications
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
ATE514729T1 (de) 1999-02-01 2011-07-15 Eidgenoess Tech Hochschule Biomaterialien die durch nukleophile reaktion auf konjugierten ungesättigten gruppen addiert sind
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6828412B1 (en) * 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
US7037992B2 (en) * 1999-09-29 2006-05-02 Sri International Olefin copolymers containing hydrolytically cleavable linkages and use thereof in degradable products
US6288184B1 (en) * 1999-09-29 2001-09-11 Sri International Hydrolytically degradable olefin copolymers
PT1455839E (pt) * 1999-10-08 2013-04-24 Nektar Therapeutics Derivados de poli(etilenoglicol) heterobifuncionais e seus métodos de preparação
ATE317868T1 (de) * 1999-12-22 2006-03-15 Nektar Therapeutics Al Corp Sterisch gehinderte derivate von wasserlöslichen polymeren
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
WO2002055185A2 (en) 2000-10-19 2002-07-18 Eidgenoess Tech Hochschule Block copolymers for multifunctional self-assembled systems
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
EP2322229B1 (de) 2001-10-10 2016-12-21 Novo Nordisk A/S Neumodulierung und Glykokonjugation von Faktor IX
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2311432B1 (de) * 2002-06-07 2014-12-24 Dyax Corporation Polypeptides mit modifizierten Kunitz Domains und deren Verwendung zur Verringerung der Ischämie oder des Beginns einer systemischen Entzündungsreaktion verbunden mit einer chirurgischen Prozedur
US7217254B2 (en) 2002-09-20 2007-05-15 Genzyme Corporation Multi-pressure biocompatible agent delivery device and method
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
US7311926B2 (en) * 2002-12-20 2007-12-25 Battelle Memorial Institute Biocomposite materials and methods for making the same
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1624847B1 (de) 2003-05-09 2012-01-04 BioGeneriX AG Zusammensetzungen und Verfahren zur Herstellung von Glykosylierungsmutanten des menschlichen Wachstumshormons
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
JP4739207B2 (ja) * 2003-08-29 2011-08-03 ダイアックス コーポレーション ポリペグ化されたプロテアーゼインヒビター
US7786213B2 (en) * 2003-10-15 2010-08-31 The Regents Of The University Of California Biomacromolecule polymer conjugates
EP2332967B1 (de) 2003-11-05 2016-04-20 Dana-Farber Cancer Institute, Inc. Stabilisierte Alpha-helix-peptide und deren Verwendungen
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
EP1722834B1 (de) * 2003-12-22 2012-06-27 Regentis Biomaterials Ltd. Matrix mit natürlich vorkommendem vernetztem proteingerüst
EP1765853B1 (de) 2004-01-08 2015-10-28 ratiopharm GmbH O-Glykosylierung von G-CSF Peptiden
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
ES2299776T3 (es) 2004-06-16 2008-06-01 Straumann Holding Ag Membrana de barrera.
US7282584B2 (en) 2004-06-16 2007-10-16 Straumann Holding Ag Methylene blue
EP1625856A1 (de) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel Polymer Prodroge Konjugate
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP2111872B1 (de) * 2004-07-05 2020-12-23 Ascendis Pharma GmbH Hydrogel-konjugate
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP3061461A1 (de) 2004-10-29 2016-08-31 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
AU2006213822B2 (en) 2005-02-09 2011-05-26 Covidien Lp Synthetic sealants
US20060222596A1 (en) 2005-04-01 2006-10-05 Trivascular, Inc. Non-degradable, low swelling, water soluble radiopaque hydrogel polymer
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2007008300A2 (en) 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2007007392A1 (ja) * 2005-07-11 2007-01-18 Wako Pure Chemical Industries, Ltd. 新規ポリマー及びこれを用いたコレステロール測定法
US8568705B2 (en) 2005-07-18 2013-10-29 Nektar Therapeutics Method for preparing branched functionalized polymers using branched polyol cores
GB0515625D0 (en) * 2005-07-29 2005-09-07 Univ Manchester Hydrogel particle
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2007112924A (ja) * 2005-10-21 2007-05-10 National Institute For Materials Science 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US7597882B2 (en) 2006-04-24 2009-10-06 Incept Llc Protein crosslinkers, crosslinking methods and applications thereof
US7872068B2 (en) 2006-05-30 2011-01-18 Incept Llc Materials formable in situ within a medical device
WO2007149594A2 (en) 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
EP2049151A4 (de) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Verfahren und zusammensetzungen zur behandlung von krebs
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008011165A2 (en) * 2006-07-21 2008-01-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
US20080081031A1 (en) 2006-09-28 2008-04-03 Schering Corporation Use of Pegylated IL-10 to Treat Cancer
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
MX2009003470A (es) 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
US8394483B2 (en) 2007-01-24 2013-03-12 Micron Technology, Inc. Two-dimensional arrays of holes with sub-lithographic diameters formed by block copolymer self-assembly
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
US8083953B2 (en) 2007-03-06 2011-12-27 Micron Technology, Inc. Registered structure formation via the application of directed thermal energy to diblock copolymer films
US8557128B2 (en) 2007-03-22 2013-10-15 Micron Technology, Inc. Sub-10 nm line features via rapid graphoepitaxial self-assembly of amphiphilic monolayers
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
US8294139B2 (en) 2007-06-21 2012-10-23 Micron Technology, Inc. Multilayer antireflection coatings, structures and devices including the same and methods of making the same
US8097175B2 (en) 2008-10-28 2012-01-17 Micron Technology, Inc. Method for selectively permeating a self-assembled block copolymer, method for forming metal oxide structures, method for forming a metal oxide pattern, and method for patterning a semiconductor structure
US7959975B2 (en) 2007-04-18 2011-06-14 Micron Technology, Inc. Methods of patterning a substrate
US8372295B2 (en) 2007-04-20 2013-02-12 Micron Technology, Inc. Extensions of self-assembled structures to increased dimensions via a “bootstrap” self-templating method
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
US8404124B2 (en) 2007-06-12 2013-03-26 Micron Technology, Inc. Alternating self-assembling morphologies of diblock copolymers controlled by variations in surfaces
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8080615B2 (en) 2007-06-19 2011-12-20 Micron Technology, Inc. Crosslinkable graft polymer non-preferentially wetted by polystyrene and polyethylene oxide
EP2195010A4 (de) * 2007-08-21 2012-03-14 Genzyme Corp Behandlung mit kallikrein-inhibitoren
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
US8999492B2 (en) 2008-02-05 2015-04-07 Micron Technology, Inc. Method to produce nanometer-sized features with directed assembly of block copolymers
US8101261B2 (en) 2008-02-13 2012-01-24 Micron Technology, Inc. One-dimensional arrays of block copolymer cylinders and applications thereof
WO2009102952A2 (en) * 2008-02-13 2009-08-20 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
JP5150297B2 (ja) * 2008-02-14 2013-02-20 ネクター セラピューティックス エイエル，コーポレイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
US8426313B2 (en) 2008-03-21 2013-04-23 Micron Technology, Inc. Thermal anneal of block copolymer films with top interface constrained to wet both blocks with equal preference
US8425982B2 (en) 2008-03-21 2013-04-23 Micron Technology, Inc. Methods of improving long range order in self-assembly of block copolymer films with ionic liquids
US8114300B2 (en) 2008-04-21 2012-02-14 Micron Technology, Inc. Multi-layer method for formation of registered arrays of cylindrical pores in polymer films
US8114301B2 (en) 2008-05-02 2012-02-14 Micron Technology, Inc. Graphoepitaxial self-assembly of arrays of downward facing half-cylinders
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
JP5435536B2 (ja) * 2008-09-04 2014-03-05 学校法人神奈川大学 光分解性ブロックコポリマー
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
WO2010067378A2 (en) 2008-12-08 2010-06-17 Reliance Life Sciences Pvt. Ltd. Hydrogel composition
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2750242C (en) 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
JP5684239B2 (ja) 2009-05-04 2015-03-11 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ Ｌｌｃ 軌道および穿刺部閉鎖用の生体材料
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
JP4704506B2 (ja) * 2009-08-11 2011-06-15 財団法人川村理化学研究所 有機無機複合ヒドロゲルおよびその製造方法
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20110081398A1 (en) * 2009-10-01 2011-04-07 Tyco Healthcare Group Lp Multi-mechanism surgical compositions
US8968785B2 (en) * 2009-10-02 2015-03-03 Covidien Lp Surgical compositions
US20110081701A1 (en) * 2009-10-02 2011-04-07 Timothy Sargeant Surgical compositions
JP5552310B2 (ja) * 2009-12-24 2014-07-16 日清紡ホールディングス株式会社 樹脂架橋剤
EP2521568B1 (de) 2010-01-06 2018-07-25 Dyax Corp. Plasmakallikreinbindende proteine
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
PT2603600T (pt) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US8304493B2 (en) 2010-08-20 2012-11-06 Micron Technology, Inc. Methods of forming block copolymers
EP2438930A1 (de) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrug mit einem exendinbindenden Konjugat
JP2014502152A (ja) 2010-11-12 2014-01-30 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 癌の治療及び診断
IL310186A (en) 2011-01-06 2024-03-01 Takeda Pharmaceuticals Co KALLIKREIN PLASMA BINDING PROTEINS
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8900963B2 (en) 2011-11-02 2014-12-02 Micron Technology, Inc. Methods of forming semiconductor device structures, and related structures
AU2012362121B2 (en) 2011-12-29 2017-08-03 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2017145921A (ru) 2012-02-15 2019-02-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
JP5953459B2 (ja) * 2012-03-27 2016-07-20 ネクター セラピューティクス ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US9087699B2 (en) 2012-10-05 2015-07-21 Micron Technology, Inc. Methods of forming an array of openings in a substrate, and related methods of forming a semiconductor device structure
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR20150131244A (ko) 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
US9229328B2 (en) 2013-05-02 2016-01-05 Micron Technology, Inc. Methods of forming semiconductor device structures, and related semiconductor device structures
CN105492460A (zh) 2013-06-14 2016-04-13 哈佛大学的校长及成员们 稳定化多肽胰岛素受体调控剂
EP3434277A1 (de) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Verfahren zur beurteilung der proteinidentität und -stabilität
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9177795B2 (en) 2013-09-27 2015-11-03 Micron Technology, Inc. Methods of forming nanostructures including metal oxides
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
CN106795506B (zh) 2014-05-14 2020-11-27 达特茅斯学院理事会 去免疫化溶葡萄球菌酶和使用方法
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CN112972378A (zh) 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3209320B1 (de) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3270945A4 (de) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selektive mcl-1-bindende peptide
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MX2017016251A (es) 2015-07-02 2018-04-20 Dana Farber Cancer Inst Inc Peptidos anti-microbianos estabilizados.
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
AU2016316842C1 (en) 2015-08-28 2021-04-22 Dana-Farber Cancer Institute, Inc. Peptides binding to BFL-1
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
JP6184462B2 (ja) * 2015-10-28 2017-08-23 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
JP7105696B2 (ja) 2016-02-29 2022-07-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
EP3503924B1 (de) 2016-08-26 2022-12-14 Dana-Farber Cancer Institute, Inc. Bcl-w-polypeptide und mimetika zur behandlung oder prävention von chemotherapieinduzierter peripherer neuropathie und hörverlust
WO2018170299A1 (en) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of prokaryotic gene transcription and uses thereof
JP6361083B2 (ja) * 2017-06-27 2018-07-25 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
WO2019018499A2 (en) 2017-07-19 2019-01-24 Dana-Farber Cancer Institute, Inc. ANTIMICROBIAL PEPTIDES STABILIZED FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS
WO2019050523A1 (en) 2017-09-07 2019-03-14 Kindheart, Inc MODIFIED ANIMAL ORGANS FOR USE IN SURGICAL SIMULATORS
US20200354413A1 (en) 2017-12-15 2020-11-12 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
EP3737404A1 (de) 2017-12-15 2020-11-18 Dana Farber Cancer Institute, Inc. Selektives targeting von apoptose-proteinen durch strukturstabilisierte und/oder cysteinreaktive noxa-peptide
US11952432B2 (en) 2018-02-07 2024-04-09 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
EP3765852A1 (de) 2018-03-14 2021-01-20 Dana Farber Cancer Institute, Inc. Stabilisierte peptide für den nachweis von biomarkern
JP6500318B2 (ja) * 2018-04-04 2019-04-17 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
EP3852783A1 (de) 2018-09-17 2021-07-28 Massachusetts Institute of Technology Für proteine der bcl-2-familie selektive peptide
CA3135115A1 (en) 2019-04-18 2020-10-22 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
CN110668933A (zh) * 2019-09-30 2020-01-10 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸（apea-7）的新方法
CN110759824A (zh) * 2019-09-30 2020-02-07 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸（apea-3）的新方法
US20230116760A1 (en) 2019-12-16 2023-04-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
AU2020408070A1 (en) 2019-12-20 2022-06-09 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
US20240124529A1 (en) 2020-03-04 2024-04-18 Dana-Farber Cancer Institute, Inc. ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
CA3179872A1 (en) 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
CA3179873A1 (en) 2020-04-27 2021-11-04 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
CN116801908A (zh) 2020-10-14 2023-09-22 丹娜法伯癌症研究院 用于降解病毒和宿主蛋白的嵌合缀合物和使用方法
EP4240395A1 (de) 2020-11-05 2023-09-13 Dana-Farber Cancer Institute, Inc. Antivirale strukturell stabilisierte ebolaviruspeptide und verwendungen davon
CA3231587A1 (en) 2021-09-08 2023-03-16 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
WO2023215784A1 (en) 2022-05-04 2023-11-09 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419006A (en) 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3963805A (en) 1974-10-30 1976-06-15 Union Carbide Corporation Water swellable poly(alkylene oxide)
DE3071070D1 (en) 1979-03-21 1985-10-17 Nat Res Dev Composition for the controlled release of a prostaglandine and process for its preparation
JPS585320A (ja) 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5334640A (en) * 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
DE4342154A1 (de) * 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
WO1996020012A2 (en) * 1994-12-23 1996-07-04 Middlesex Sciences, Inc. Methods for preparing and purifying macromolecular conjugates
WO1997005185A2 (en) 1995-07-28 1997-02-13 Focal, Inc. Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
EP0787749B1 (de) * 1995-08-23 2003-04-02 Mitsui Chemicals, Inc. Neue allylether, polymere und feste polymer-elektrolyte
ZA978537B (en) * 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
ZA987019B (en) 1997-08-06 1999-06-04 Focal Inc Hemostatic tissue sealants
US6316522B1 (en) * 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
AU755051B2 (en) * 1998-01-07 2002-12-05 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6326276B1 (en) * 1999-08-10 2001-12-04 United Microelectronics Corp. Method for forming a capacitor in dram

Also Published As

Publication number Publication date
CA2316834A1 (en) 1999-07-15
US6362276B1 (en) 2002-03-26
US8497357B2 (en) 2013-07-30
AU2221499A (en) 1999-07-26
EP1053019B1 (de) 2003-12-03
AU755051B2 (en) 2002-12-05
US20110009589A1 (en) 2011-01-13
PT1053019E (pt) 2004-04-30
CA2316834C (en) 2006-01-03
ES2211033T3 (es) 2004-07-01
US20120195846A1 (en) 2012-08-02
US20040086992A1 (en) 2004-05-06
US20070292931A1 (en) 2007-12-20
JP2003510375A (ja) 2003-03-18
JP3786832B2 (ja) 2006-06-14
US7166304B2 (en) 2007-01-23
WO1999034833A1 (en) 1999-07-15
US20040086991A1 (en) 2004-05-06
EP1053019A1 (de) 2000-11-22
DE69913316T2 (de) 2004-11-18
ATE255422T1 (de) 2003-12-15
DK1053019T3 (da) 2004-04-13
US7214388B2 (en) 2007-05-08
US20010016624A1 (en) 2001-08-23
WO1999034833A9 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
DE69913316D1 (de) Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
PT1028753E (pt) Libertacao de moleculas de poli(etilenoglicol)-conjugado a partir de hidrogeles degradaveis
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
ES2121180T3 (es) Sintesis mejorada de conjugados de polimero/sustancia bioactiva.
MY131553A (en) Lyophilized formulation of polyethylene oxide modified proteins with increased self-life
KR19980701305A (ko) 1,3,7-옥타트리엔등의 공액 폴리엔으로부터 제조되는 가교결합된 중합체(crosslinked polymers made from 1,3,7-octatriene and like conjugated polyenes)
CA2301533A1 (en) Balloons made from liquid crystal polymer blends
NZ337845A (en) Non-antigenic branched polymer conjugates
DK0621880T3 (da) Lægemiddelafgivelsessystem til samtidig afgivelse af lægemidler, der kan aktiveres af enzymer og lys
CA2174325A1 (en) Non-antigenic branched polymer conjugates
CA2191567A1 (en) Individualized Cellulosic Fibers Crosslinked with Polyacrylic Acid Polymers
AU2658495A (en) Absorbent structure containing individualized cellulosic fibers crosslinked with polyacrylic acid polymers
CA2268433A1 (en) Improved interferon polymer conjugates
ES2156893T3 (es) Polimeros biodegradables de trasplante de celulas.
WO1988000837A3 (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
DK97987A (da) Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation
AU3470600A (en) Compositions and methods for drug delivery
AU4646397A (en) Polymeric membranes and polymer articles having hydrophilic surface and method for their preparation
AU4660789A (en) Polypeptide derivatives
GT200200038A (es) Conjugados peg de hgf-nk4
UA32522C2 (uk) Ліофілізована протипухлинна композиція і стерильна водна композиція для ін'єкцій на її основі
AU6889196A (en) Long active composition for rectal administration
CA2445841A1 (en) Uses of chemically-modified cholinesterases for detoxification of organophosphorus compounds
NZ334592A (en) Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer
EP0838224A3 (de) Polymer - Arzneimittel Konjugate mit einer enzymspaltbaren Linker

Legal Events

Date Code Title Description
8364 No opposition during term of opposition